Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;48(12): 1109-1114, Dec. 2015. graf
Artículo en Inglés | LILACS | ID: lil-762913

RESUMEN

Diabetic retinopathy (DR) is a serious complication of diabetes mellitus that may result in blindness. We evaluated the effects of activation of endogenous angiotensin converting enzyme (ACE) 2 on the early stages of DR. Rats were administered an intravenous injection of streptozotocin to induce hyperglycemia. The ACE2 activator 1-[[2-(dimethylamino) ethyl] amino]-4-(hydroxymethyl)-7-[[(4-methylphenyl) sulfonyl] oxy]-9H-xanthone 9 (XNT) was administered by daily gavage. The death of retinal ganglion cells (RGC) was evaluated in histological sections, and retinal ACE2, caspase-3, and vascular endothelial growth factor (VEGF) expressions were analyzed by immunohistochemistry. XNT treatment increased ACE2 expression in retinas of hyperglycemic (HG) rats (control: 13.81±2.71 area%; HG: 14.29±4.30 area%; HG+XNT: 26.87±1.86 area%; P<0.05). Importantly, ACE2 activation significantly increased the RCG number in comparison with HG animals (control: 553.5±14.29; HG: 530.8±10.3 cells; HG+XNT: 575.3±16.5 cells; P<0.05). This effect was accompanied by a reduction in the expression of caspase-3 in RGC of the HG+XNT group when compared with untreated HG rats (control: 18.74±1.59; HG: 38.39±3.39 area%; HG+XNT: 27.83±2.80 area%; P<0.05). Treatment with XNT did not alter the VEGF expression in HG animals (P>0.05). Altogether, these findings indicate that activation of ACE2 reduced the death of retinal ganglion cells by apoptosis in HG rats.


Asunto(s)
Animales , Masculino , Hiperglucemia/complicaciones , Peptidil-Dipeptidasa A/metabolismo , Enfermedades de la Retina/etiología , Enfermedades de la Retina/prevención & control , Prevención Secundaria/métodos , Administración Oral , Apoptosis , /metabolismo , Proliferación Celular/fisiología , Supervivencia Celular/fisiología , Diabetes Mellitus Experimental/metabolismo , Activación Enzimática , Hiperglucemia/inducido químicamente , Inmunohistoquímica , Peptidil-Dipeptidasa A/efectos de los fármacos , Ratas Wistar , Enfermedades de la Retina/metabolismo , Células Ganglionares de la Retina/metabolismo , Células Ganglionares de la Retina/patología , Estreptozocina , Factor A de Crecimiento Endotelial Vascular/metabolismo , Xantonas/administración & dosificación
2.
Braz J Med Biol Res ; 48(12): 1109-14, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26421871

RESUMEN

Diabetic retinopathy (DR) is a serious complication of diabetes mellitus that may result in blindness. We evaluated the effects of activation of endogenous angiotensin converting enzyme (ACE) 2 on the early stages of DR. Rats were administered an intravenous injection of streptozotocin to induce hyperglycemia. The ACE2 activator 1-[[2-(dimethylamino) ethyl] amino]-4-(hydroxymethyl)-7-[[(4-methylphenyl) sulfonyl] oxy]-9H-xanthone 9 (XNT) was administered by daily gavage. The death of retinal ganglion cells (RGC) was evaluated in histological sections, and retinal ACE2, caspase-3, and vascular endothelial growth factor (VEGF) expressions were analyzed by immunohistochemistry. XNT treatment increased ACE2 expression in retinas of hyperglycemic (HG) rats (control: 13.81±2.71 area%; HG: 14.29±4.30 area%; HG+XNT: 26.87±1.86 area%; P<0.05). Importantly, ACE2 activation significantly increased the RCG number in comparison with HG animals (control: 553.5±14.29; HG: 530.8±10.3 cells; HG+XNT: 575.3±16.5 cells; P<0.05). This effect was accompanied by a reduction in the expression of caspase-3 in RGC of the HG+XNT group when compared with untreated HG rats (control: 18.74±1.59; HG: 38.39±3.39 area%; HG+XNT: 27.83±2.80 area%; P<0.05). Treatment with XNT did not alter the VEGF expression in HG animals (P>0.05). Altogether, these findings indicate that activation of ACE2 reduced the death of retinal ganglion cells by apoptosis in HG rats.


Asunto(s)
Hiperglucemia/complicaciones , Peptidil-Dipeptidasa A/metabolismo , Enfermedades de la Retina/etiología , Enfermedades de la Retina/prevención & control , Prevención Secundaria/métodos , Administración Oral , Enzima Convertidora de Angiotensina 2 , Animales , Apoptosis , Caspasa 3/metabolismo , Proliferación Celular/fisiología , Supervivencia Celular/fisiología , Diabetes Mellitus Experimental/metabolismo , Activación Enzimática , Hiperglucemia/inducido químicamente , Inmunohistoquímica , Masculino , Peptidil-Dipeptidasa A/efectos de los fármacos , Ratas Wistar , Enfermedades de la Retina/metabolismo , Células Ganglionares de la Retina/metabolismo , Células Ganglionares de la Retina/patología , Estreptozocina , Factor A de Crecimiento Endotelial Vascular/metabolismo , Xantonas/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA